Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAl-Mustafa University College

About this trial

The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10% intravenous solution in cutaneous leishmaniasis as a local injection.

In a randomized parallel groups clinical trial, patients were divided into two groups based on therapeutic regimen: 1) intralesional sodium stibogluconate weekly injection and 2) intralesional ciprofloxacin injection. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis

Disqualifiers

Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study

patients on prolonged corticosteroid therapy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ciprofloxacin (BAYO9867)

    Drug

    Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).

  • sodium stibogluconate (Pentostam)

    Drug

    Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: intralesional ciprofloxacinExperimental treatment 1 intervention
Group B: intralesional sodium stibogluconateActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Cure rate

Patients were followed weekly up to 90 days after the first injection; four parameters were used for assessment as follows according to Sharquie modified leishmania score: 1. Measure the size of the lesion through the surface area 2. Measurement of the induration of the lesion 3. Assess the degree of erythema of the lesion 4. Assess the presence and absence of ulceration The obtained data is converted from numbers into scores. The total score was calculated by adding individual scores. Score 13-16: Mild response. Score 9-12: Moderate response. Score 5-8: Marked response. Score 0-4: Complete response \& clearance Both marked and complete responses are considered as a cure

Time frame
From enrollment to the end of treatment up to 90 days.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Al-Mustafa University College

Lead sponsor

Al-Mustansiriyah University

Collaborator